| drug | Clevidipine |
| classification | Calcium Channel Blocker, Arterial Vasodilator |
| pharmacokinetics | | absorption | Rapidly absorbed through intravenous administration. Bioavailability is nearly complete. Extensive first-pass metabolism is insignificant. | | distribution | Extensively distributed throughout the body, although limited penetration across the blood-brain barrier. High protein binding (94-98%). | | metabolism | Metabolized primarily by ester hydrolysis, occurring in plasma and erythrocytes; limited renal metabolism. | | excretion | Eliminated as metabolites primarily through the liver. No significant renal excretion. |
|
| suggested dosage | | adults | | notes | Initial dose and subsequent titration are crucial in managing blood pressure. Consult specific patient guidelines and monitoring parameters. | | range | Initial dose: 0.5–2 mcg/kg/min; titrated up gradually every 2-5 minutes. Maximum dose is 20-60 mcg/min, often in the range of 2-15 mcg/min. |
| | patient specific factors | | 1 | Individual patient's response and hemodynamic status | | 2 | Presence of any underlying conditions |
|
|
| indications | | 1 | Hypertension crisis management (severe hypertension) | | 2 | Hypertensive emergencies | | 3 | Short-term control of blood pressure in critically ill patients |
|
| safety in pregnancy | | category | C | | notes | Limited data available on the use of clevidipine in pregnancy. Potential risks to the developing fetus are unclear; careful consideration is needed. Benefit-risk assessment must be conducted on a case-by-case basis. Consult with specialist. |
|
| safety in breastfeeding | | notes | Limited data available on the excretion of clevidipine into breast milk. Due to the potential for adverse effects on the infant, caution is advised. The drug's potential for harm and the benefits of breastfeeding should be thoroughly considered. |
|
| side effects | | 1 | Hypotension (most common) | | 2 | Headache | | 3 | Nausea | | 4 | Vomiting | | 5 | Flushing | | 6 | Tachycardia | | 7 | Dizziness | | 8 | Edema | | 9 | Dyspnea | | 10 | Cardiac events | | 11 | Local reactions at the infusion site (infrequently) |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity to clevidipine or soybean or egg ingredients (emulsifier) | | 2 | Severe hypotension | | 3 | Severe bradycardia | | 4 | Shock |
|
| interactions | | 1 | Drugs that inhibit or induce CYP3A4 (rarely clinically significant) | | 2 | Concomitant use with other vasodilators may increase the risk of hypotension | | 3 | Other drugs with potential blood pressure lowering effects |
|
| warnings and precautions | | 1 | Careful monitoring of blood pressure and heart rate is essential throughout treatment | | 2 | Close monitoring for the development of hypotension, bradycardia, or other adverse reactions | | 3 | Potential for severe hypotension if the dose is not titrated properly | | 4 | Risk of rebound hypertension if the infusion is stopped abruptly | | 5 | Patients with a history of significant coronary disease should be treated with caution | | 6 | Monitoring lipid levels is crucial due to the lipid content of the formulation |
|
| additional information | | 1 | Clevidipine is an intravenous medication. Only qualified healthcare providers should administer it. | | 2 | It should be infused in lipid-containing emulsions. This necessitates careful monitoring of lipid parameters if infusion time exceeds 48 hours | | 3 | The lipid content of the infusion must be accounted for in patients with lipid disorders or high risk for these conditions. Strict adherence to administration guidelines and monitoring protocols is critical. Proper disposal of unused solution is mandatory. |
|
| patient specific considerations | | 1 | | factor | Age | | notes | General considerations, monitoring needed |
| | 2 | | factor | Weight | | notes | Use weight-based dosing; adjust for comorbidities |
| | 3 | | factor | Other Medical Conditions | | notes | Adjust dosage and monitoring based on concurrent disease/conditions |
| | 4 | | factor | Medications | | notes | Carefully assess for drug interactions; adjust for concomitant therapies |
|
|
| patient age | 25 years |
| patient weight | 70 kg |
